Bioxcel Therapeutics, INC. (BTAI) — SEC Filings

Overview

Bioxcel Therapeutics, INC. (BTAI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 27, 2026: BioXcel Therapeutics, Inc. filed an 8-K on March 27, 2026, reporting on its financial condition and results of operations. The filing includes financial statements and exhibits, with the primary document being the 8-K itself in iXBRL format.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 46 neutral. The dominant filing sentiment for Bioxcel Therapeutics, INC. is neutral.

Filing Type Overview

Bioxcel Therapeutics, INC. (BTAI) has filed 41 8-K, 5 10-Q, 1 10-K, 1 DEF 14A, 1 SC 13G/A, 1 SC 13D/A with the SEC between Jun 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 8-K Filing — 8-K · Apr 1, 2026
• BioXcel Therapeutics Files 8-K on Financials — 8-K · Mar 27, 2026 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on March 27, 2026, reporting on its financial condition and results of operations. The filing includes financial stateme
• BioXcel Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Dec 15, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on a submission of matters to a vote of security holders that occurred on December 12, 2
• BioXcel's Losses Widen Amidst Plummeting IGALMI Sales — 10-Q · Nov 12, 2025 Risk: high
  BioXcel Therapeutics, Inc. (BTAI) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $57.35 million, up from $48
• 8-K Filing — 8-K · Nov 10, 2025
• BioXcel Therapeutics Files Routine 8-K — 8-K · Oct 30, 2025 Risk: low
  On October 30, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates no specific material events or changes requiring immediate disclosure
• BioXcel Therapeutics Files 8-K — 8-K · Oct 14, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting an 'Other Event'. The filing does not contain specific details about the event itself, bu
• BioXcel Therapeutics Files 8-K — 8-K · Sep 15, 2025 Risk: medium
  BioXcel Therapeutics, Inc. filed an 8-K on September 15, 2025, reporting on events that occurred on the same date. The filing is primarily a Regulation FD Discl
• BioXcel Therapeutics Files 8-K: Other Events — 8-K · Sep 10, 2025 Risk: medium
  On September 10, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are n
• BioXcel Therapeutics Files 8-K — 8-K · Aug 27, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on August 27, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the even
• BioXcel Therapeutics to be Acquired by Jabbok Affiliate — 8-K · Aug 18, 2025 Risk: medium
  BioXcel Therapeutics, Inc. announced on August 18, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Jabbok, LLC. The tran
• BioXcel Therapeutics to be Acquired by Kindred Biosciences Affiliate — 8-K · Aug 15, 2025 Risk: medium
  BioXcel Therapeutics, Inc. announced on August 14, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Kindred Biosciences,
• BioXcel Therapeutics Files 8-K — 8-K · Aug 12, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• BioXcel Fuels Operations with $3.1M Equity Raise Amidst Zero Revenue — 10-Q · Aug 12, 2025 Risk: high
  BioXcel Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss
• BioXcel Therapeutics Files 8-K — 8-K · Aug 11, 2025 Risk: low
  On August 11, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material e
• BioXcel Therapeutics Files 8-K — 8-K · Aug 6, 2025 Risk: medium
  BioXcel Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting an "Other Event." The filing does not contain specific details about the event, its nature,
• BioXcel Therapeutics Files 8-K — 8-K · Aug 1, 2025 Risk: medium
  BioXcel Therapeutics, Inc. filed an 8-K on August 1, 2025, reporting an 'Other Event'. The filing does not contain specific details about the event, dollar amou
• BioXcel Therapeutics Files 8-K — 8-K · Jul 21, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on July 21, 2025, reporting other events. The company, incorporated in Delaware with its principal executive offices in
• BioXcel Therapeutics Files 8-K: Other Events — 8-K · Jul 15, 2025 Risk: medium
  On July 15, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are not el
• BioXcel Therapeutics Files 8-K: Other Events — 8-K · May 27, 2025 Risk: medium
  BioXcel Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events
• BioXcel Therapeutics Files 8-K on Financials — 8-K · May 12, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on May 12, 2025, to report on its results of operations and financial condition. The filing includes financial statement
• BioXcel Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  BioXcel Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business oper
• BioXcel Therapeutics Enters Material Definitive Agreement — 8-K · Apr 3, 2025 Risk: medium
  BioXcel Therapeutics, Inc. announced on April 3, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its
• BioXcel Therapeutics Files 2024 10-K — 10-K · Mar 28, 2025 Risk: medium
  BioXcel Therapeutics, Inc. filed its 2024 10-K on March 28, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company
• BioXcel Therapeutics Files 8-K on Financials — 8-K · Mar 27, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• BioXcel Therapeutics Files 8-K for Other Events — 8-K · Mar 21, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on March 21, 2025, reporting an event that occurred on March 20, 2025. The filing pertains to 'Other Events' and does no
• BioXcel Therapeutics Enters Material Definitive Agreement — 8-K · Mar 4, 2025 Risk: medium
  On March 3, 2025, BioXcel Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement or a
• BioXcel Therapeutics Files 8-K — 8-K · Mar 3, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on March 3, 2025, reporting an event on February 28, 2025. The filing is categorized under 'Other Events' and does not s
• BioXcel Therapeutics Files 8-K with Corporate Updates — 8-K · Feb 6, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on February 6, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements with exhib
• BioXcel Therapeutics Files 8-K on Shareholder Votes — 8-K · Jan 29, 2025 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on January 29, 2025, reporting on matters submitted to a vote of security holders as of January 28, 2025. The filing det
• BioXcel Therapeutics Announces Board and Executive Changes — 8-K · Jan 16, 2025 Risk: medium
  BioXcel Therapeutics, Inc. announced on January 15, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• BioXcel Therapeutics Announces Board and Executive Changes — 8-K · Jan 8, 2025 Risk: medium
  BioXcel Therapeutics, Inc. announced on January 7, 2025, a change in its board of directors and executive compensation arrangements. The filing details the depa
• BioXcel Therapeutics Files Definitive Proxy Statement — DEF 14A · Dec 30, 2024 Risk: low
  BioXcel Therapeutics, Inc. filed its definitive proxy statement on December 30, 2024, for its annual meeting of stockholders scheduled for January 28, 2025. The
• BioXcel Therapeutics Enters Material Definitive Agreement — 8-K · Nov 25, 2024 Risk: medium
  BioXcel Therapeutics, Inc. announced on November 22, 2024, that it entered into a material definitive agreement. The filing does not provide specific details on
• BioXcel Therapeutics Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Nov 21, 2024 Risk: medium
  BioXcel Therapeutics, Inc. filed an 8-K on November 21, 2024, reporting on several key events. These include entering into a material definitive agreement, unre
• BioXcel Therapeutics Files 8-K for Financials — 8-K · Nov 14, 2024 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on November 14, 2024, to report on its results of operations and financial condition, as well as to file financial state
• BioXcel Therapeutics Q3 2024 Update: Cash Position and Offerings — 10-Q · Nov 14, 2024 Risk: medium
  BioXcel Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $42.46 million as of Septe
• BioXcel Therapeutics Appoints New CMO, Director — 8-K · Oct 9, 2024 Risk: medium
  BioXcel Therapeutics, Inc. announced on October 3, 2024, the appointment of Dr. Robert J. Henninger as Chief Medical Officer and the election of Dr. William D.
• BioXcel Therapeutics Faces Delisting Notice — 8-K · Sep 20, 2024 Risk: high
  BioXcel Therapeutics, Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, inco
• BioXcel Therapeutics: CMO Departs, New Directors Appointed — 8-K · Sep 19, 2024 Risk: medium
  BioXcel Therapeutics, Inc. announced on September 17, 2024, the departure of its Chief Medical Officer, Dr. Robert L. Neville. The company also elected two new
• SC 13G/A Filing — SC 13G/A · Sep 10, 2024
• BioXcel Therapeutics to be Acquired by Kindred Biosciences Affiliate — 8-K · Sep 9, 2024 Risk: medium
  BioXcel Therapeutics, Inc. announced on September 5, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Kindred Biosciences
• BioXcel Therapeutics to be Acquired for $1.1 Billion — 8-K · Sep 5, 2024 Risk: medium
  BioXcel Therapeutics, Inc. announced on September 5, 2024, that it has entered into a definitive agreement to be acquired by J.P. Morgan Acquisition Corp. for a
• BioXcel Therapeutics Files 8-K on Financials — 8-K · Aug 6, 2024 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
• BioXcel Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 6, 2024 Risk: medium
  BioXcel Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business opera
• BioXcel Therapeutics Enters Material Definitive Agreement — 8-K · Jul 17, 2024 Risk: medium
  BioXcel Therapeutics, Inc. announced on July 11, 2024, that it entered into a material definitive agreement. The company, incorporated in Delaware with its prin
• BioXcel Therapeutics Files 8-K — 8-K · Jul 16, 2024 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on July 16, 2024, to report on its results of operations and financial condition, as well as to file financial statement
• BioXcel Sells Neuroscience Drug Candidate to Sun Pharma for $10M — 8-K · Jun 25, 2024 Risk: medium
  BioXcel Therapeutics, Inc. announced on June 25, 2024, that it has entered into a definitive agreement to sell its neuroscience drug candidate, BXCL-501, to a s
• BioXcel Therapeutics Files 8-K on Corporate Changes — 8-K · Jun 12, 2024 Risk: low
  BioXcel Therapeutics, Inc. filed an 8-K on June 12, 2024, reporting on events that occurred on June 10, 2024. The filing indicates changes to the company's arti
• BioXcel Holdings & Vimal Mehta Amend 13D Filing — SC 13D/A · Jun 6, 2024 Risk: medium
  On June 6, 2024, BioXcel Holdings, Inc. and Vimal Mehta filed an amendment (Amendment No. 1) to their Schedule 13D for BioXcel Therapeutics, Inc. The filing ind

Risk Profile

Risk Assessment: Of BTAI's 47 recent filings, 3 were flagged as high-risk, 25 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bioxcel Therapeutics, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0.39M
• Net Income: -$57.35M
• EPS: -$2.18
• Debt-to-Equity: N/A
• Cash Position: $36.18M
• Operating Margin: N/A
• Total Assets: $44.79M
• Total Debt: $92.30M

Key Executives

• Dr. Robert J. Henninger
• Dr. William D. Young
• Dr. Robert L. Neville
• Dr. Jonathan M. Rothberg
• Mr. David E. Singer
• Vimal Mehta

Industry Context

BioXcel Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing novel therapies. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies, often requiring substantial capital.

Top Tags

8-K (10) · sec-filing (5) · regulatory-filing (5) · filing (5) · material-agreement (5) · financial-reporting (4) · disclosure (4) · 8-k (4) · corporate-event (4) · acquisition (4)

Key Numbers

• Net Loss: $57.35M — for the nine months ended September 30, 2025, increased from $48.74M in 2024
• Product Revenue: $0.39M — for the nine months ended September 30, 2025, a significant decrease from $1.90M in 2024
• Cash and Cash Equivalents: $36.18M — as of September 30, 2025, up from $29.85M at December 31, 2024
• Accumulated Deficit: $707.55M — as of September 30, 2025, indicating substantial historical losses
• Common Shares Outstanding: 21,869,491 — as of November 11, 2025, significantly increased from 3,102,000 at December 31, 2024
• Interest Expense: $12.59M — for the nine months ended September 30, 2025, up from $11.10M in 2024
• Total Operating Expenses: $40.57M — for the nine months ended September 30, 2025, down from $58.65M in 2024
• Commission File Number: 001-38410 — SEC identifier for BioXcel Therapeutics
• EIN: 82-1386754 — Employer Identification Number
• I.R.S. Employer Identification No.: 82-1386754 — Company's tax identification number
• Revenue: $0 — for the three and six months ended June 30, 2025, indicating no commercial products generating sales
• Gross Proceeds: $3.1M — from the March 2025 offering, highlighting reliance on equity financing
• Shares Issued: 1,000,000 — in the March 2025 offering, contributing to shareholder dilution
• Shares Available: 3,102,000 — for future awards under the 2020 Incentive Award Plan as of June 30, 2025, indicating potential future dilution
• Total Assets: 3102000 — As of March 31, 2025

Related Companies

BXTL · BXcel · KIND · BXCL · KNDX

Frequently Asked Questions